Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
Status:
Withdrawn
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this pilot study is to assess the pharmacokinetic profile of low-dose
bevacizumab and its effectiveness in reducing plasma free VEGF-A levels safely in
hemodialysis patients. This information will be used to plan a phase 1 clinical trial
evaluating bevacizumab's role in hemodialysis vascular access failure.